Loading

JSM Nutritional Disorders

Respiratory Disease Screening as an Adverse Effect and Associated Factors of COVID 19 Recovered Patients from Quiha Treatment Center in Mekelle, Tigray, Ethiopia, 2020: A Community Based Institutional Study

Original Research | Open Access Volume 3 | Issue 1 |

  • 1. Abreha Tsegay Gebreselassie (MSc), Department of Psychiatry, College of health science, Mekelle University, Mekelle, Tigray, Ethiopia
  • 2. Werkua Mekonen (MSc), Department of Psychiatry, College of health science, Mekelle University, Mekelle, Tigray, Ethiopia
+ Show More - Show Less
Corresponding Authors
Abreha Tsegay, Department of Psychiatry, College of health science, Mekelle University, Mekelle, Tigray, Ethiopi
Abstract

Background: Coronavirus (COVID-19) is an illness caused by a virus that can spread from person to person. The virus that causes COVID-19 is a new coronavirus that has spread throughout the world. COVID-19 symptoms can range from mild (or no symptoms) to severe illness. In late December 2019, investigation of a cluster of pneumonia cases of unknown origin in Wuhan, China resulted in identification of a novel coronavirus. The virus is distinct from both severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), although closely related.

Objective: to assess respiratory disease screening as an adverse effect and associated factors of COVID-19 recovered patients from a treatment center in Mekelle, Tigray, Ethiopia.

Methods: a community based quantitative study design was conducted among 600 samples in Mekelle town, Tigray, Ethiopia. Data were collected using a structured and semi-structured questionnaire. Associations between dependent and independent variables were tested using logistic regression with the assumptions of p-values < 0.05 and confidence interval 95% and considered to be statistically significant.

Results: the prevalence of respiratory disease after screening using CRQ was 24.3%. Variable like who read and wrote [AOR=2.859, 95% CI: 1.349- 6.063, P=0.006]. COVID 19 symptoms such as those who had shortness of breathing [AOR=3.485, 95% CI: 1.776-6.838, P=0.001], sore throat [AOR=4.645, 95% CI: 2.107-10.242, P=0.001], and chest pain pressure was AOR=3.453, 95%CI: 1.484-8.037, P=0.04] were significant factor for respiratory disease.

Conclusion: The study found that the prevalence of respiratory disease after screening using CRQ was 24.3%. Variables such as read and write, shortness of breathing, sore throat, and pneumonia were significant factors for respiratory disease.

Keywords

•    Respiratory disease
•    COVID-19
•    Screening, CRQ
•    Treatment center
•    Ethiopia

Citation

Tsegay A, Muluye G, Mekonen W, Gebrehiwot B (2021) Respiratory Disease Screening as an Adverse Effect and Associated Factors of COVID 19 Recovered Patients from Quiha Treatment Center in Mekelle, Tigray, Ethiopia, 2020: A Community Based Institutional Study. JSM Nutr Disord 3(1): 1009.

ABBREVIATIONS

ANOVA: One-way analysis of variance Aor: Adjusted odds ratio, ARDS: Acute Respiratory Distress Syndrome, CDC: Disease Control and Prevention, CI: Confidence interval, COR: Crude odds ratio, COVID-19: Coronavirus disease, CRQ: Chronic respiratory questionnaires, FDA: Food and drug administration, HRERC: Health Research Ethics Review Committee, SARS: Severe acute respiratory syndrome, SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, SPSS: Statistical Package for Social Sciences, WHO: World health organization.

INTRODUCTION

COVID-19 is a respiratory virus and disease. It is spread by small droplets from coughs and sneezes and from touching infected surfaces. At least 80 % of people who are infected with the virus will have anywhere from no symptoms to mild to moderate flu-like symptoms, including a fever and cough and the remaining 20 % may develop more severe cases of coronavirus that may develop pneumonia or severe acute respiratory syndrome.

The Centers for Disease Control and Prevention (CDC) estimate that 3-17% of COVID-19 patients develop a complication known as Acute Respiratory Distress Syndrome (ARDS). ARDS patients lose the ability to breathe normally and this is known as a respiratory failure that results from severe inflammation in the lungs. Risk factors for developing pneumonia from COVID-19 include diabetes, hypertension, chronic heart, chronic lung disease, immune-suppressed conditions, being elderly (increasing age), and obesity.

COVID-19 is a viral infection caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that primarily targets the respiratory system, with initial symptoms often including shortness of breath and fever (1). Emerging infectious diseases, such as severe acute respiratory syndrome (SARS) and Zika virus disease, present a major threat to public health (2). In late December 2019, a cluster of patients was admitted to hospitals with an initial diagnosis of pneumonia of an unknown etiology. These patients were epidemiologically linked to the seafood and wet animal wholesale market in Wuhan, Hubei Province, China (3).

According to world meters info reported that globally, 41,169,789 cases and 1,131,329 deaths were encountered within 213 countries since last December 2019 due to COVID 19 until now there is no treatment or vaccination found.

The clinical manifestations of COVID-19 are protean, which include an asymptomatic carrier, ARD, and pneumonia of varying degrees of severity. First, asymptomatic cases were diagnosed based on positive viral nucleic acid test results, but without any COVID-19 symptoms, such as fever, gastrointestinal, or respiratory symptoms, and no significant abnormalities on chest radiograph (4).

There are currently no appropriate scientifically approved vaccines/drugs for COVID-19. Nonetheless, few broad-spectrum antiviral drugs, azithromycin were tested against COVID-19 in clinical trials, and finally, food and drug administration (FDA) approved emergency use of remdesivir in hospitalized COVID-19 patients (5).

Convalescent plasma therapy is effective and specific for COVID?19 and this intervention has a special significance for eliminating SARS-CoV-2 and is believed to be a promising state-of-the-art therapy during the COVID-19 pandemic crisis (6).

Levels of potassium, albumin, and lymphocytes were increased persistently after treatment from sustained lopinavir use. Increasing eosinophils may be an indicator of COVID-19 improvement. Viral load of SARS-CoV-2, radiography, and eosinophil improved continuously not more than 9 days (7).

A study done in China reported that urea nitrogen concentration at admission was associated with the presence of CT abnormalities (P = 0.046, AOR= 7.149, 95% CI: 1.038 - 49.216). Lung function abnormalities were detected in 14 patients and the measurement of D-dimer levels at admission may be useful for prediction of impaired diffusion defect (P = 0.031, AOR =1.06, 95% CI:1.006 -1.129). Radiological and physiological abnormalities were still found in a considerable proportion of COVID-19 survivors without critical cases 3 months after discharge. A higher level of D-dimer on admission could effectively predict impaired DLCO after 3 months of discharge (8).

Post-mortem studies have noted diffuse alveolar damage, leading some to postulate that long-term pulmonary sequelae are possible from COVID-19, such as interstitial pulmonary fibrosis (1 ). Besides, based on the literature from other viral infections, reduced or abnormal pulmonary function may be expected in people with COVID-19 in the months after recovery, although there are limited studies to date evaluating pulmonary function (10).

The long-term effect of COVID-19 is still largely unknown. However, based on previous experiences with other viral pulmonary infections, long-term pulmonary consequences are indeed expected in some patients. A significant number of patients recovering from the acute viral illness may have significant impairment in overall functional capacity and specifically their pulmonary function in the first few months (11).

The predominant pattern of lung lesions in patients with COVID-19 patients is diffuse alveolar damage, as described in patients infected with severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses. Hyaline membrane formation and pneumocyte atypical hyperplasia are frequent. Importantly, the presence of platelet–fibrin thrombi in small arterial vessels is consistent with coagulopathy, which appears to be common in patients with COVID-19 and should be one of the main targets of therapy (12).

The pooled analysis revealed that common complications up to 6 months after discharge were: impaired diffusing capacity for carbon monoxide (prevalence 27%, 95% confidence interval (CI) 15–45%); and reduced exercise capacity (mean 6-min walking distance 461 m, CI:450–473 m). Low scores on Short-Form 36 were identified beyond 6 months after discharge (13).

The study reported that 11.4% presented with at least one GI symptom (nausea, vomiting, or diarrhea), and 10.8% had pre-existing liver disease. Of patients with COVID-19 with GI symptoms, 17 (22.97%) had severe/critical types. Of patients with COVID-19 with GI symptoms, 29 (39.19%), 23 (31.08%), 8 (10.81%), and 16 (21.62%) had significantly higher rates of fever >38.5°C, fatigue, shortness of breath, and headache, respectively. Sputum production and increased lactate dehydrogenase/ glucose levels were risk factors for severe/critical type (14).

A study was done revealed the prevalence of smell and taste of COVID 19 clients was 68% and 71% respectively. Smell and taste impairment [AOR=10.9, 95% CI: 5.08-23.15] was significant with COVID 19 (15). The conceptual framework of the adopted literature review can see in (Fig 1).

Conceptual framework of respiratory disease screening as an adverse effect and associated factors of COVID 19 recovered patients from treatment center in  Mekelle, Tigray, Ethiopia, 2020 (n=600).

Figure 1: Conceptual framework of respiratory disease screening as an adverse effect and associated factors of COVID 19 recovered patients from treatment center in Mekelle, Tigray, Ethiopia, 2020 (n=600).

To my knowledge so far, there is no research conducted that screening respiratory disease of recovered COVID-19 patients. So that the purpose of the study is to give an emphasis and base researchers to conduct a cohort study. Moreover, the study helps physicians to have foci on respiratory disease treatment to those who were recovered from the treatment center.

METHOD AND MATERIALS

Study area and period

The study was conducted in 2020 in the city of Mekelle Northern Ethiopia. Mekelle city which was founded in the 13th century is the capital city of the Tigray region. It is located 783 km north of Addis Ababa and its elevation is 2,084 meters above sea level with an area of 24.4 square kilometers. Administratively Mekelle is considered a special zone, which is divided into seven sub-cities namely: Hawelti, Adi Haki, Kedamay Weyane, Hadnet, Ayder, Semien, and Quia. The city has one specialized hospital (Ayder), three general hospitals (Mekelle, Quiha, and North command military hospital), nine health centers (Mekelle, Semien, Kasech, Quiha, Aynalem, Hawelti, Felegado Adha and Adishimdihun) and several private clinics and private hospitals. According to the 2011 Census, the total population of the city is about 367,470 (186,045 males and 181,376 females); and approximately half of the inhabitants are younger than 20 years old. Tigrigna is spoken as a first language by (96.26%) and (2.98%) speak Amharic. The majority of the population (91.31%) practiced Ethiopian Orthodox Christianity, and 7.66% are Muslim and the remaining practiced other religions. There is 1 COVID 19 treatment center found in Quiha Sub-city. There are more than 6000 COVID 19 infected cases in Mekelle City, of those 5000 clients recovered and 50 deaths since the emerging pandemic disease to Ethiopia.

Study design

A community-based cross-sectional survey was employed.

Source population

The target population is all COVID 19 clients of the city of Mekelle.

Study population

All COVID 19 clients of Mekelle city were found in the randomly selected sub-cities.

Sample population

All COVID 19 sampled clients of Mekelle city who are found in the households (selected using systematic random sampling method)

Eligibility criteria

Inclusion criteria: All COVID 19 recovered clients who are greater than 18 years old and agreed to participate in the study were included.

Exclusion criteria: Respondents with incomplete information of the COVID 19 recovered clients and with any form of memory problem, psychiatric client, not volunteer to participate would not be included in the study.

Sample size and sampling procedure

Sample size determination: The actual sample size for the study will be determined using the formula for a single population proportion by assuming 5% marginal error (d), 95% confidence interval (alpha=0.05), and taking the proportion of respiratory disease 50% because there was no study done in else area.

Based on the above information the total initial sample

size was calculated by using the formula; n=\frac{\left (Z\alpha /2 \right )^{2}\times P\left ( 1-P \right )}{\left ( d \right )^{2}} . \frac{\left ( 1.96 \right )^{2}\times0.304\left ( 1-0.304 \right ) }{\left ( 0.05 \right )^{2}}

Where; n= required an initial sample size

Zα/2 =critical value for normal distribution at a 95% confidence interval which equals to

1.96 (Z value at alpha=0.05).

P= Proportion will be 50%.

d= marginal error (0.05).

This yield to n= 384 Adding a 10% non-response rate and considering 1.5 design effect the total household required for this study will be 600 clients.

4 Sub cities will be selected randomly, from these selected sub-cities, 3 Kebeles will be selected randomly from each sub cities. Then the 600 clients will be selected using a systematic random sampling method (Figure 2).

Sampling procedures for selecting clients, Mekelle town, Tigray, Ethiopia, 2020.

Figure 2: Sampling procedures for selecting clients, Mekelle town, Tigray, Ethiopia, 2020.

Sampling technique and procedure: The systematic sampling technique was employed. The study participants were proportionally allocated in all kebeles and clients selected systematically from these kebeles (Figure 2).

Data collection procedure: Face to face interview with keeping personal protective equipment’s like sanitizer, facemask method using a structured questionnaire was used in this study to identify respiratory diseases screening such as (1) sociodemographic characteristics, (2) medical characteristics (3) coronavirus variables (4) SRQ-20, and (5) CRQ. Also, the chart was reviewed to check the psychiatric and other medical illness diagnoses and investigations. During the interview, pneumonic clients were referred to the hospital; and severe mentally distressed consulted for clinical psychological for further psychiatric evaluation.

Self-reported questionnaire 20 (SRQ-20) was developed by the World health organization (WHO) and is an instrument with 20 items to assess neurotic disorder. The tool is suitable for selfadminister and interviewer-administered questionnaires. Each of the 20 items is scored 0 or 1. A score of 1 indicates the symptom was present during the past month, a score of 0 indicates that the symptom was absent. The maximum score, therefore, is 20. The tool was valid in WHO and Ethiopia as well. The Cronbach’s alpha was 0.85.in addition to English, SRQ was used in Arabic, Eritrea (Tigrigna), Amharic (Ethiopia), Italian, Hindi, French, and Malaysia are some of the common (16).

The Chronic Respiratory Questionnaire (CRQ) is an established measure of health status, which had been widely used for research purposes. The CRQ-SR was found to be reproducible both in the short term and after a long period of 7 weeks. The CRQ is divided into four dimensions of dyspnea, fatigue, emotional function, and mastery (the patient’s feeling of control over their disease). The patient is required to identify everyday activities which make them breathless and then select rank and score the five most important activities on a sevenpoint scale which spans from 1-’extremely short of breath’ to 7 ‘not at all short of breath’. Every patient will have a unique list of activities. In each dimension the lower the score, the greater the degree of dysfunction. Averagely classifying the scale into 4 main classes and those are dyspnea, fatigue, emotion, and mastery. The magnitude of respiratory disease was calculated as CRQ below mean had no respiratory disease and mean and above mean had the respiratory disease (17). The tool was valid in Ethiopian settings, the reliability test was done and the Cronbach’s alpha for CRQ was 0.87.

Data Collection Instrument: A structured and pre-tested questionnaire was used for data collection. The questionnaire was first prepared in English and then translated into Tigrigna and back-translated into English by different qualified individuals to check the consistency. The training was given for data collectors and supervisors. COVID -19 Recovered participants were interviewed by six trained midwifery/nurses that deliver reproductive health service at the time of data collection, data collectors using face to face interview technique. Besides, trained supervisors who have a master of public health (MPH) level professionals and principal investigators were supervised the work.

Study Variables

Dependent Variable: Respiratory Disease screening.

Independent Variables

Socio-demographic status: age, educational status, occupation, family perceived income status, marital status, number of children

Operational Definition

Respiratory disease or lung diseases: a type of disease that affects the lungs and other parts of the respiratory system.

Chronic respiratory diseases (CRDs): are diseases of the airways and other structures of the lung.

CRQ screening: a procedure that is performed to identify the presence of respiratory disease symptoms in the recovered participants in the short term and after a longer period of 7 weeks.

Have CRQ: those respondents who were scored mean and the above mean of the respiratory disease screening CRQ assessing questions.

Have no CRQ: those respondents who were scored below the mean of the respiratory disease screening CRQ assessing questions.

Mental distress (or psychological distress): is a term used to describe a range of symptoms and experiences of a person’s internal life that are commonly held to be troubling, confusing, or out of the ordinary.

Have SRQ-20 (have mental distress): those respondents who were scored 6 and above from SRQ-20 items after assessing clients in the past 1 month.

Have no SRQ-20 (have no mental distress): those respondents who were scored 5 and below from SRQ-20 items after assessing clients in the past 1 month.

DATA COLLECTION TOOLS AND PROCEDURES

A structured and pre-tested questionnaire was used for data collection. The questionnaire was first prepared in English and then translated into Tigrigna and back-translated into English by different qualified individuals to check the consistency. The training was given for data collectors and supervisors. Clients were interviewed by six trained midwiferies/nurses that deliver reproductive health service at the time of data collection, data collectors using face to face interview technique. Also, trained supervisors who have MPH level professionals and principal investigators were supervised the work.

Data collection tools and quality controls

To achieve good data quality:

The questionnaire was prepared in English and translated into Tigrigna and back-translated to English to keep the consistency of the data.

A structured questionnaire that is adapted from different literature is used.

The training was provided to the selected data collectors and supervisors for three days about the objective and process of data collection, including pre-testing. If there were problems in the questionnaire explanation was provided.

Pre-testing was done with 5% of the questionnaires, in a similar area that is not included in the study.

Data Analysis

The collected data were entered, edited, and cleaned in Epidata Version 4.3 and then it was exported to SPSS Version 25 for analysis. After the data is preprocessed then descriptive statistics of the study variables were presented using frequencies and percentages for the categorical variables. The presence of an association between knowledge of cervical cancer, attitude, and practice to its screening and the independent variables was tested using cross-tabulation with the chi-square test at P-value < 0.05 significance level.

As the dependent variable cervical cancer is with two categories, binary logistic regression analysis was used. In the bivariate logistic regression, the level of significance of the association between the dependent and each independent variable was considered at P-value < 0.05, and the factors with this level of significance were made to pass on to the next level of analysis. In the multivariable logistic regression analysis, the Stepwise forward predictor inclusion method was used to develop the main-effect model for the dependent variable cervical cancer. The presence and significance of interaction terms and confounding effects on the main effect model were checked using the Log-likelihood ratio test and the percentage change in beta values of the independent variables.

Multi-collinearity between independent variables also checked using variance inflation factors considering multi-co linearity at variance inflation factor (VIF) >10. The presence and influence of outliers were checked using residuals cooks distance and influence statistic. A comparison between models was made using the log-likelihood ratio test. The goodness of fit of the model was checked using the Hosmer Lemeshow test of goodness of fit. The proportion of correctly classified observations was checked using the classification table, and the prediction power of the model was checked using the area under the receiver operating characteristics (ROC) curve.

RESULT

Sociodemographic characteristics

The total study participants were 600 clients who recovered from COVID 19 treatment center. Of the total 307(51.2%) males and 293(48.8%) female; 116(30%) who achieve the highest level of education was primary school; 463(77.2) live with their family whereas 137(22.8) live alone; 272(45.3) single in marital status; 228(38.0) unemployed and 115(19.2) housewife in occupation participated. There were 272(45.3) single, 230(38.3) married, and 98(16.3) divorced participants clients in marital status.

Participants their age ranges 145(24.2) 25-31 years, 138(23.0) 32-38 years, 46 years and above 114(19.0); mean=2.988, mode=2.00, and Std. Deviation=1.35 (Table 1).

Table 1: Sociodemographic characteristics of respiratory disease screening as an adverse effect and associated factors of COVID 19 recovered patients from treatment center in Mekelle, Tigray, Ethiopia, 2020 (n=600).

Variables

Categories

Respiratory Disease as an Adverse effect

No

Yes

 

 

 

 

Age

 

 

 

 

 

 

 

 

 

Sex Live with

 

Marital status Occupation

 

 

 

 

 

Educational status

 

 

 

18-24 Year

76(16.7)

22(15.1)

 

 

 

25-31 Year

116(25.6)

29(19.9)

 

 

 

32-38 Year

110(24.2)

28(19.2)

 

 

 

38-45 Year

69(15.2)

36(24.7)

 

 

 

≥46 Year

83(18.3)

31(21.2)

Male

228(50.2)

79(54.1)

Female

226(49.8)

67(45.9)

Alone

103(22.7)

34(23.3)

With family

351(77.3)

112(76.7)

Single

4545.4)

66(45.2)

Married

172(37.9)

59(39.7)

Divorced/widowed/

76(16.7)

22(15.1)

Unemployed

181(39.9)

47(32.2)

Housewife

85(18.7)

30(20.5)

Daily laborer

34(7.5)

13(8.9)

Government employee

60(13.2)

24(16.4)

Farmer

45(9.9)

14(9.6)

Merchant

23(5.1)

8(5.5)

Student

26(5.7)

10(6.8)

Illiterate

109(24.0)

25(17.1)

Read and write

37(8.1)

22(15.1)

Primary school

88(19.4)

28(19.2)

Secondary school

145(29.7)

45(30.8)

 

 

 

Tertiary school

85(18.7)

26(17.8)

Medical characteristics

Regarding substance, 534(89.0) had no smoking cigarette habit and the rest 66(11.0) had habit; 518(86.3) had a habit of alcohol drinking and 82(13.7) had a habit. The current status of treatment of adverse effects of COVID 19 clients, 514(85.7) had no treatment whereas 84(14.3) were in the treatment. From the total participants, 475(79.2) had no comorbid disease whereas the rest 125(20.8) had a comorbid physical illness. Of the total participant clients, 237(39.5) had no comorbid with the disease, 124(20.7) had gastrointestinal and the rest 239(39.8) had both cardiovascular and respiratory diseases (Table 2).

Table 2: Medical characteristics of respiratory disease screening as an adverse effect and associated factors of COVID 19 recovered patients from treatment center in Mekelle, Tigray, Ethiopia, 2020 (n=600).

 

Variables

 

Categories

Respiratory Disease as an Adverse effect

No

Yes

 

 

 

Current status treatment adverse effect of COVID 19

 

 

Diagnosis of comorbid physical illness

 

 

Smoking Habit Drinking Habit

Patient's comorbid disease with COVID 19

 

 

 

 

 

No

388(85.5)

126(87.5)

 

 

 

 

Yes

66(14.5)

18(12.5)

 

 

 

 

No

359(79.1)

116(79.5)

 

 

 

 

Yes

95(20.9)

30(20.5)

 

 

 

 

No

406(89.4)

128(87.7)

 

Yes

48(10.6)

18(12.3)

 

No

398(87.7)

120(82.2)

 

Yes

56(12.3)

26(17.8)

 

No

171(37.7)

68(46.6)

 

Gastrointestinal disease

7(7.0)

11(7.8)

 

Cardiovascular disease

57(12.6)

22(15.1)

 

Respiratory disease

194(42.7)

42(30.2)

Reporting the COVID stage during treatment, 70(11.7) asymptomatic, 284(47.3) experienced mild symptoms, 175(29.2) serious/severe and 71(11.8) were critical while in the treatment center. Results showed what happens after recovered of COVID 19, 107(17.8) had no disease, 246(41.0) had developed the respiratory disease, 247(41.2) develop kidney and heart diseases.

Results showed that staying at the hospital and discharged from treatment institution, 290(48.3) discharged after 3 weeks stay, 196(32.7) 4-5 weeks stay, and 114(19.0) 6-9 weeks stay. Of the total participants, almost all 571(95.2) did not experience mental distress whereas only 29(4.8) clients were distressed mentally and consulted for clinical psychological for further psychiatric evaluation.

Regarding the COVID 19 exposure, 349(58.2) participants had travel history, 149(24.8) had contact history from the confirmed case and 102(17.0) had no travel history or no contact with the confirmed case. The study revealed regarding COVID 19 symptoms that 133(22.2) had fever greater than 38 degree Celsius, 168(28.0) had a dry cough, 106(17.7) had shortness of breathing, 54(9.0) had a sore throat, 93(15.5) had fatigue and 46(7.8) had chest pain or pressure (Table 3).

Table 3: Corona virus characteristics of respiratory disease screening as an adverse effect and associated factors of COVID 19 recovered patients from treatment center in Mekelle, Tigray, Ethiopia, 2020 (n=600).

Variables

Categories

Respiratory Disease as an Adverse effect

No

Yes

 

 

 

 

 

 

 

COVID 19 stage during treatment

 

 

 

 

 

 

Experienced after of COVID 19 recovered

 

Respiratory disease Questionnaire

 

 

COVID19 treatment duration

 

 

Mental distress COVID19 exposure

 

 

COVID 19 symptoms

 

 

 

 

 

Asymptomatic

51(11.2)

19(13.0)

 

 

 

 

Mild

210(46.3)

74(50.7)

 

 

 

 

Serious/severe

136(30.0)

39(26.7)

 

 

 

 

Critical

57(12.6)

14(9.6)

 

 

 

 

No disease

74(16.3)

33(22.6)

 

Respiratory disease

191(42.1)

55(37.7)

 

Kidney and heart disease

189(41.6)

58(39.7)

 

Dyspnea

222(48.9)

76(52.1)

 

Fatigue

141(31.1)

30(20.5)

 

Emotion

50(11.0)

18(12.3)

 

Mastery

41(9.0)

22(15.1)

 

3 weeks

226(49.8)

64(43.8)

 

4-5 weeks

146(32.2)

50(34.2)

 

6-9 weeks

82(18.1)

32(21.9)

 

No

429(94.5)

142(97.3)

 

Yes

25(5.5)

4(2.7)

 

Travel history

262(57.7)

87(59.6)

 

Contact history

116(25.6)

32(21.9)

 

No known history of contact or travel

76(16.7%)

27(18.5)

 

Fever(>38)

114(25.2)

19(13.0)

 

Dry cough

137(30.2)

31(21.2)

 

Shortness of breathing

69(15.2)

37(25.3)

 

Sore throat

33(7.3)

21(14.4)

 

Fatigue

70(15.5)

23(15.8)

 

Chest pain or pressure

6(6.6)

15(10.3)

6.3. Prevalence of Chronic Respiratory Questionnaires (CRQ):

The prevalence of respiratory disease after the screening was 146(24.3%) with 95%CI: 23.09-25.58; whereas those who had not respiratory disease symptoms after discharged from COVID 19 treatment were 75.7% (454) from 600 sampled participants. The study found that 298(49.7) dyspnea, 171(28.5) fatigue, 68(11.3) emotion, and 63(10.5) mastery responded to the CRQ tool (Fig 3).

Chronic respiratory Questionnaires of respiratory disease screening as an adverse effect and associated factors of COVID 19 recovered patients from treatment  center in Mekelle, Tigray, Ethiopia, 2020 (n=600).

Figure 3: Chronic respiratory Questionnaires of respiratory disease screening as an adverse effect and associated factors of COVID 19 recovered patients from treatment center in Mekelle, Tigray, Ethiopia, 2020 (n=600).

Associated factors of respiratory disease screening as an adverse effect

The study found that those who read and wrote were 2.859 times more likely to have the respiratory disease than those illiterate [AOR=2.859, 95% CI: 1.349-6.063, P=0.006]. COVID 19 symptoms

such as those who had shortness of breathing during infection were 3.48 times more likely to have the respiratory disease than asymptomatic [AOR=3.485, 95% CI: 1.776-6.838, P=0.001], sore throat was 4.64 times likely to have the respiratory disease [AOR=4.645, 95% CI: 2.107-10.242, P=0.001], and chest pain pressure was 3.45 times more likely to have the respiratory disease [AOR=3.453, 95%CI: 1.484-8.037, P=0.04]. However, age, alcohol, developed the disease after COVID 19, CRQ, and mental distress were not significant factors in this study (Table 4).

Table 4: Multiple logistic regression analysis of respiratory disease screening as an adverse effect and associated factors of COVID 19 recovered patients from treatment center in Mekelle, Tigray, Ethiopia, 2020 (n=600) Note: bolded indicates variables which show significant factors with respiratory disease at multivariate analysis.

Variables

Categories

Yes

No

COR(95% CI)

AOR(95%CI)

P value

 

Age

 

25-31 year

32-38 year

39-45 year

≥46 year

 

18-24 year

31(21.2)

36(24.7)

28(19.2)

29(19.9)

 

22(15.1)

83(18.3)

69(15.2)

110(24.2

116(25.6)

 

76(16.7)

.864[.462-1.614]

.879[.468-1.652]

1.802[.967-3.359]

1.290[.688-2.420]

 

 

1

 

.818[.419-1.596]

.831[.420-1.646]

1.749[.883-3.467]

1.234[.618-2.462]

.556

.596

.109

.551

 

Education

 

Read and write Primary school Secondary school Tertiary school Illiterate

22(15.1)

88(19.4)

45(30.8)

26(17.8)

25(17.1)

37(8.1)

28(19.2)

145(29.7)

85(18.7)

109(24.0)

 

2.592[1.309-5.136]

1.387[.755-2.548]

1.453[.838-2.520]

1.334[.719-2.474]

1

 

2.859[1.349-6.063]

1.194[.618-2.306

1.619(.877-2.990)

1.255[.637-2.475]

 

.006

.597

.123

.511

 

Alcohol

Yes No

26(17.8)

398(87.7)

56(12.3)

120(82.2)

1.540[.927-2.559]

1

1.604[.914-2.815]

.100

Developed disease after COVID 19

Respiratory Disease Kidney and Heart Disease

 

191(42.1)

189(41.6)

33(22.6)

55(37.7)

58(39.7)

74(16.3)

 

.646[.388-1.073]

.688[.415-1.140]

1

 

.678[.381-1.208]

.721[.401-1.295]

 

.187

.273

No Disease

 

 

 

 

CRQ

Dyspnea Fatigue

 

76(52.1)

30(20.5)

18(12.3)

41(9.0)

222(48.9)

141(31.1)

.638[.357-1.139]

.397[.207-.760]

 

.673[.403-1.124]

.998[.514-1.937]

1.325[.700-2.509]

.130

.995

Emotion

50(11.0)

.671[.318-1.417]

.387

Mastery

22(15.1)

1

 

 

Mental distress

Yes No

4(2.7)

142(97.3)

25(5.5)

429(94.5)

.483[.165-1.413]

1

.439[.141-1.373]

.157

 

 

COVID 19 symptoms

Cough Shortness of breathing

Sore throat Fatigue Pneumonia

Fever

31(21.2)

37(25.3)

21(14.4)

23(15.8)

6(6.6)

19(13.0)

137(30.2)

69(15.2)

33(7.3)

70(15.5)

15(10.3)

114(25.2)

1.358[.728-2.531]

3.217[1.716-6.034]

3.818[1.837-7.936]

1.971[1.002-3.878]

3.000[1.365-6.593]

1

1.480[.764-2.870]

3.485[1.776-6.838]

4.645[2.107-10.242]

1.997[.969-4.115]

3.453[1.484-8.037]

.245

.0001

.0001

.061

.004

 

DISCUSSION

COVID-19 is, emerged in china in December 2019; an infectious pandemic disease affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization. The characterized by most common symptoms: fever, dry cough, tiredness; less common symptoms: aches and pains, sore throat, diarrhea, headache; and serious symptoms: shortness of breath, chest pain, or pressure.

The finding of the prevalence of respiratory disease after the screening was 24.3%. There is no study reported this instead other studies reported either the pathophysiology or effects after investigation or post-mortem.

The study showed that the prevalence of gastrointestinal symptoms was 7.8%, which is lower than with a study done by 11.4% in China. This could be due to sample size, the period, pandemic disease emerging. The prevalence of COVID 19 symptoms: was fever=13.0%. This very lower than a study done this is 39.19%. This might be due to herd immunity and illness status. The second COVID 19 symptom was shortness of breathing=25.3% prevalent. This result is very higher than in China which is 10.81%. This could be due to using modernized intervention in a developed country. The third COVID 19 symptoms were fatigue=15.8% and are contrasted lower than with study done in other which is 31.08%. This could be due to lifestyle modification, herd immunity, and illness status (18).

The study revealed that educational status (read and wrote) was associated with respiratory disease. This might be due to the sample size of the COVID 19 infected participants. No study was done regarding this and cannot compare and contrast with studies because this study was only taken from client verbal than client and laboratory investigation, and imaging like other studies done reported that other viral infections, reduced or abnormal pulmonary function may be expected in people with COVID-19 in the months after recovery (19); other viral pulmonary infections, long-term pulmonary consequences are indeed expected in some patients (20); hyaline membrane formation and pneumocyte atypical hyperplasia are frequent; sputum production and increased lactate dehydrogenase/glucose levels were risk factors for severe/critical type (21).

Regarding the COVID 19 symptoms: dry cough; shortness of breathing; and chest pain and pressure were significant associated with respiratory disease. This is due to the pandemic disease symptoms had a dry cough, smothering so that almost all COVID 19 infected clients had such symptoms. This result compares with a study in another area that is the clinical manifestations of COVID-19 symptoms: fever which is not a significant factor for both studies; whereas gastrointestinal, or respiratory symptoms, and no significant abnormalities on chest radiograph (22).

CONCLUSION

The study found that the prevalence of respiratory disease after screening using CRQ was 24.3%. Variables such as read and write, shortness of breathing, sore throat, and pneumonia were significant factors for respiratory disease.

RECOMMENDATION

For health professionals to examine, diagnose, and treat as early as possible to reduce complication to those who had developed respiratory disease

It helps as a base for researchers to conduct cohort study, study design with investigations and imaging, qualitative as well.

LIMITATION OF THE STUDY

Study design: since the study design is cross-sectional, by nature, does not show the cause and for showing the temporal relationship.

This study is original; first, study as far as our knowledge, it left many things

The study didn’t include physical examination, laboratory investigations, and imaging, it is only verbal information from the clients what happen during and after the treatment.

DECLARATIONS

Ethics approval and consent to participate

Ethical approval was obtained from the ethical review committee of Tigrain Health Institute and the Tigray Regional Health Bureau, which was confirmed to the principles embodied in the Declaration of Helsinki. Official permission was also obtained from the principals of the health facilities before approaching the study participants. The objective and purpose of the study were clearly explained to the study subjects to obtain written informed consent before data collection. Participants were also informed that they can discontinue or decline to participate in the study at any time. Confidentiality of the information was maintained and the data were recorded anonymously throughout the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal.

Consent for publication

Tigrain Health Institute, the Tigray Regional Health Bureau, and participants are for this section.

Availability of data and material

All availability of data and material is attached to the manuscript.

Competing interests

The authors declare that they have no competing interests regarding employment or voluntary involvement; collaborations with advocacy groups relating to the content of the article; grants from an entity paid to the author or organization; personal fees received by the author/s as honoraria, royalties, consulting fees, lecture fees, testimonies, etc.; patents held or pending by the authors, their institutions or funding organizations, or licensed to an entity whether earning royalties or not; involvement in legal action related to the work.

AUTHORS’ CONTRIBUTIONS

AT had made substantial contributions to the conception, design of the work;GM had the acquisition, analysis, interpretation of data; WM had a contribution to the creation of new software used in the work; have drafted the work or substantively revised it. The authors have approved the submitted version (and any substantially modified version that involves the author’s contribution to the study); and to have agreed both be personally accountable for the author’s contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. All authors have read and approved the manuscript.

ACKNOWLEDGMENTS

Our sincere thanks go to Tigrain Health Institute and Tigray Regional Health Bureau at admission. The study was approved by the Research Ethics Commission of Tigrain Quiha COVID Hospital Treatment Center staff for the information given on COVID-19 confirmed cases, recoveries and deaths and in general data used for this research, and participants without whom this thesis would not be realized.

REFERENCES

1. Rothan, H. A. and S. N. Byrareddy. “The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 102433.

2. Ventura C.V, et al. Zika virus in Brazil and macular atrophy in a child with microcephaly. Lancet. 2016; 387: 228.

3. Bogoch, I I., et al. Pneumonia of unknown etiology in Wuhan, China: potential for international spread via commercial air travel. J Travel Med.2020; 27: 008.

4. Macera M, et al. Clinical presentation of COVID-19: case series and review of the literature.Int J Environ Res Public Health. 2020; 17: 5062.

5. Jamwal S, et al. An updated insight into the molecular pathogenesis, secondary complications, and potential therapeutics of COVID-19 pandemic. Life Sci. 2020; 118105.

6. Ye, M, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020; 25882.

7. Liu F, et al. Patients of COVID-19 may benefit from sustained lopinavir combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int Infect Dis. 2020; 95: 183-191.

8. Zhao Ym, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020; 25: 100463.

9. Carsana L, et al.. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-center descriptive study. Lancet Infect Dis. 2020; 20: 1135-1140.

10. Salehi S, et al. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. Am J Roentgenol. 2019; 215: 87-93.

11. Xie L, et al. Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge. Chest. 2005; 127: 2119-2124.

12. Carsana L, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-center descriptive study. Lancet Infectious Diseases. 2020; 20: 1135-1140.

13. Ahmed H, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalization or ICU admission: a systematic review and meta-analysis. J Rehabi Med. 2020; 52: 00063.

14. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, Hao SR, Jia HY, Cai H, Zhang XL, Yu GD. Epidemiological, clinical, and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020; 69: 1002- 1009.

15. Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza?like symptoms. Int Forum Allergy Rhinol. 2020; 10: 806- 813.

16. Netsereab TB, Kifle MM, Tesfagiorgis RB, Habteab SG, Weldeabzgi YK, Tesfamariam OZ. Validation of the WHO self-reporting questionnaire-20 (SRQ-20) item in primary health care settings in Eritrea. Int J Ment Health Syst. 2018; 12: 1-9.

17. Williams J E, et al. Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax. 2001; 56: 954-959.

18. Salehi, S, et al. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol. 2020; 215: 87-93.

19. Xie L, et al. Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge. Chest. 2005; 127: 2119-2124.

20. Macera M, et al. Clinical presentation of COVID-19: case series and review of the literature. Int J Environ Res Public Health. 2020; 17: 5062.

Tsegay A, Muluye G, Mekonen W, Gebrehiwot B (2021) Respiratory Disease Screening as an Adverse Effect and Associated Factors of COVID 19 Recovered Patients from Quiha Treatment Center in Mekelle, Tigray, Ethiopia, 2020: A Community Based Institutional Study. JSM Nutr Disord 3(1): 1009.

Received : 22 May 2021
Accepted : 23 Jun 2021
Published : 24 Jun 2021
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X